1. |
Zhu W, Zhu D, Lu S, et al.miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2[J].Med Oncol, 2012, 29(1):384-391.
|
2. |
Manne U, Shanmugam C, Bovell L, et al.miRNAs as biomarkers for management of patients with colorectal cancer[J].Biomark Med, 2010, 4(5):761-770.
|
3. |
Ishida M, Selaru FM.miRNA-based therapeutic strategies[J].Curr Anesthesiol Rep, 2013, 1(1):63-70.
|
4. |
Gao M, Yin H, Fei ZW.Clinical application of microRNA in gastric cancer in Eastern Asian area[J].World J Gastroenterol, 2013, 19(13):2019-2027.
|
5. |
Furuta M, Kozaki K, Tanimoto K, et al.The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma[J].PLoS One, 2013, 8:e60155.
|
6. |
Shen L, Li J, Xu L, et al.miR-497 induces apoptosis of breast cancer cells by targeting bcl-w[J].Exp Ther Med, 2012, 3(3):475-480.
|
7. |
Zhao WY, Wang Y, An ZJ, et al.Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer[J].Biochem Biophys Res Commun, 2013, 435(3):466-471.
|
8. |
Pan HW, Li SC, Tsai KW.MicroRNA dysregulation in gastric cancer[J].Curr Pharm Des, 2013, 19(7):1273-1284.
|
9. |
Shah AA, Leidinger P, Backes C, et al.A set of specific miRNAs is connected with murine and human gastric cancer[J].Genes Chromosomes Cancer, 2013, 52(3):237-249.
|
10. |
Hagiwara K, Ochiya T, Kosaka N.A paradigm shift for extracellular vesicles as small RNA carriers:from cellular waste elimination to therapeutic applications[J].Drug Deliv Transl Res, 2014, 4:31-37.
|
11. |
Kye MJ, Gonçalves Ido C.The role of miRNA in motor neuron disease[J].Front Cell Neurosci, 2014, 8:15.
|
12. |
Cui L, Zhang X, Ye G, et al.Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer[J].Cancer, 2013, 119(9):1618-1626.
|
13. |
Luo Q, Li X, Gao Y, et al.MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer[J].Cancer Cell Int, 2013, 13(1):95.
|
14. |
Guo ST, Jiang CC, Wang GP, et al.MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer[J].Oncogene, 2013, 32(15):1910-1920.
|
15. |
Navarro SJ, Trinh T, Lucas CA, et al.The C57BL/6J mouse strain background modifies the effect of a mutation in Bcl2l2[J].G3(Bethesda), 2012, 2(1):99-102.
|
16. |
Kawasaki T, Yokoi S, Tsuda H, et al.BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line[J].Cancer Sci, 2007, 98(7):1070-1077.
|
17. |
Zhang YW, Zhang YL, Pan H, et al.Chemotherapy for patients with gastric cancer after complete resection:A network meta-analysis[J].World J Gastroenterol, 2014, 20(2):584-592.
|
18. |
Baroudi O, Baroudi T, Omrane I, et al.Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population:a predictive role in 5-fluorouracil based chemotherapy treatment[J].Med Oncol, 2014, 31(2):825.
|
19. |
Ina K, Kataoka T, Ando T.The use of lentinan for treating gastric cancer[J].Anticancer Agents Med Chem, 2013, 13(5):681-688.
|
20. |
Ishigami S, Arigami T, Uenosono Y, et al.Outcomes of advanced gastric cancer patients treated with chemoradiation therapy[J].Gan To Kagaku Ryoho, 2013, 40(6):727-731.
|